1 research outputs found
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
To describe healthcare costs of patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapies from a US payer perspective. Patients initiating a Flatiron oncologist-defined 1L mCRPC therapy (index date) on or after mCRPC diagnosis were identified from linked electronic medical records/claims data from the Flatiron Metastatic Prostate Cancer (PC) Core Registry and Komodo’s Healthcare Map. Patients were excluded if they initiated a clinical trial drug in 1L, had Among 459 patients with mCRPC (mean age 70 years, 57% White, 16% Black, 45% commercially-insured, 43% Medicare Advantage-insured, and 12% Medicaid-insured), average baseline all-cause total costs (PPPM) were 4,166 pre-mCRPC progression, 2,935 (6,661 post-mCRPC progression). During an average 1L duration of 8.5 months, mean total costs were 12,061 (PC-related) PPPM. The cost increase following 1L therapy initiation was driven by higher PC-related outpatient and pharmacy costs. PC-related medical costs PPPM increased from 5,585 following 1L mCRPC therapy initiation. All analyses were descriptive; statistical testing was not performed. Incremental costs of progression to mCRPC are significant, with the majority of costs driven by higher PC-related costs. Using contemporary data, this study highlights the importance of utilizing effective therapies that slow progression and reduce healthcare resource demands despite the initial investment in treatment costs.</p